Issue Date: August 21, 2006
Novozymes will acquire GroPep
Novozymes has agreed to acquire the Australian biotechnology company GroPep for almost $65 million. GroPep manufactures Long R3 IGF-1, a growth factor supplement used to produce vaccines, monoclonal antibodies, and other recombinant proteins in mammalian cell-based manufacturing systems that don't use animal serum as a cell nutrient source. GroPep had sales last year of $12.7 million, almost all from Long R3 IGF-1.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society